Moleculin Biotech Inc (NASDAQ: MBRX) has seen a rise in its stock price by 8.49 in relation to its previous close of 1.06. However, the company has experienced a 5.50% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-24 that Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp – Chairman and CEO John Paul Waymack – Senior CMO Jonathan Foster – EVP and CFO Conference Call Participants Jonathan Aschoff – Roth Capital Partners Jason McCarthy – Maxim Group Vernon Bernardino – H.C. Wainwright Operator Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Moreover, the 36-month beta value for MBRX is 2.18. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MBRX is 13.19M and currently, short sellers hold a 8.20% of that float. On March 26, 2025, MBRX’s average trading volume was 5.82M shares.
MBRX’s Market Performance
MBRX stock saw an increase of 5.50% in the past week, with a monthly gain of 7.48% and a quarterly increase of -36.46%. The volatility ratio for the week is 13.40%, and the volatility levels for the last 30 days are 15.32% for Moleculin Biotech Inc (MBRX). The simple moving average for the last 20 days is 0.13% for MBRX stock, with a simple moving average of -52.01% for the last 200 days.
Analysts’ Opinion of MBRX
Oppenheimer, on the other hand, stated in their research note that they expect to see MBRX reach a price target of $14. The rating they have provided for MBRX stocks is “Outperform” according to the report published on July 18th, 2022.
MBRX Trading at -12.79% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.56% of loss for the given period.
Volatility was left at 15.32%, however, over the last 30 days, the volatility rate increased by 13.40%, as shares sank -10.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.88% lower at present.
During the last 5 trading sessions, MBRX rose by +5.50%, which changed the moving average for the period of 200-days by -76.48% in comparison to the 20-day moving average, which settled at $1.1485. In addition, Moleculin Biotech Inc saw -32.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBRX
Current profitability levels for the company are sitting at:
- -71.22 for the present operating margin
- 0.76 for the gross margin
The net margin for Moleculin Biotech Inc stands at -74.26. The total capital return value is set at -1.62. Equity return is now at value -135.80, with -78.93 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -47.8. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -65.87.
Currently, EBITDA for the company is -26.52 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 15.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
To wrap up, the performance of Moleculin Biotech Inc (MBRX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
